---
title: "atezolizumab"
date: "2024-01-23"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Monoclonal Antibodies]]

# atezolizumab

- Atezolizumab (Tecentriq)
- Mechanism: Binds to **PD-L1**
- Dosing:
  - 840 mg every 2 wks,
  - 1,200 mg IV every 3 wks,
  - or 1,680 mg every 4 wks; hold for hepatic tox,
  - â†‘ Scr,
  - & immune-mediated AEs
- PK/PD: T1/2 âˆ¼27 d
- AEs:
  - Immune-mediated tox,
  - lymphocytopenia,
  - GI tox,
  - rash,
  - infusion rxn,
  - metabolic abnormalities,
  - pneumonitis,
  - â†‘ liver enzymes,
  - endocrinopathies
- DDI: No known pathways of metabolism
- Clinical pearls:
  - Tx immune-related tox w/ steroids (prednisone 1-2 mg/kg/d),
  - WARN: **can increase complications post allogeneic HSCT**

### Backlink

- [[Treatment of hepatocellular carcinoma]]
- [[SCLC staging and treatment]]
- [[Polymorphisms]]
- [[PD-L1]]
- [[Overview-immunotherapy and cellular therapy]]
- [[Monoclonal Antibodies]]
